Skip to main content
MDxHealth SA logo

MDxHealth SA — Investor Relations & Filings

Ticker · MDXH ISIN · BE0974461940 LEI · 549300J3MG9F9B5FY646 BR Human health and social work activities
Open in API
Filings indexed 940 across all filing types
Latest filing 2024-05-01 Interim / Quarterly Rep…
Country BE Belgium
Listing BR MDXH

About MDxHealth SA

https://mdxhealth.com/

MDxHealth SA is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize the diagnosis and treatment of urologic conditions. The company's portfolio of tests is designed to assist clinicians in making more informed decisions. For prostate cancer, its products include Select mdx, which assesses a patient's risk to help determine if a biopsy can be safely avoided; Confirm mdx, which addresses biopsy sampling errors; and the GPS (Genomic Prostate Score) test, a genomic assay that helps guide treatment decisions for men with localized disease. Additionally, the company offers Resolve mdx, a test that aids in selecting appropriate treatment for patients presenting with symptoms of urinary tract infections (UTIs).

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, MDxHealth SA, with the SEC. It contains detailed information about a new Credit Agreement, a Sales Agreement for equity offering, and includes unaudited interim condensed financial statements for the three months ended March 30, 2024. The presence of interim financial statements with substantive financial data and analysis indicates this is a comprehensive quarterly report rather than a mere announcement or certification. The Form 6-K is used by foreign private issuers to report material information, including interim financial results. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-05-01 English
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an 'at the market offering' of ordinary shares by MDxHealth SA. It includes detailed information about the offering, the sales agreement with TD Securities, risk factors, use of proceeds, and other related disclosures. The document is a formal offering document used to raise capital through the sale of shares. This type of document is classified as a Capital/Financing Update because it provides updates on the company's fundraising activities and capital structure changes. It is not an annual or interim report, earnings release, or any other type of report or announcement. The document length is substantial (15,000 characters), and it contains detailed offering terms, confirming it is not merely an announcement or a brief summary.
2024-04-30 English
ANNUAL REPORT
Annual Report FY 2023
2024-04-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release attached as Exhibit 99.1 dated March 12, 2024. The document itself is short (2076 characters) and primarily serves to furnish information rather than provide detailed financial data or a full report. It explicitly states that the attached press release is not "filed" for certain regulatory purposes and is not incorporated by reference. There is no substantive financial data or detailed report content within this document. According to the rules, such a document is a regulatory filing that does not fit into other specific categories and is best classified as Regulatory Filings (RNS).
2024-03-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release attached as Exhibit 99.1 dated March 6, 2024. The document is relatively short (2074 characters) and primarily serves to furnish information rather than provide detailed financial data or comprehensive reports. It explicitly states that the attached press release is being furnished and not filed for purposes of Section 18 of the Exchange Act. There is no substantive financial data or detailed report content within this document itself. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 6-K filings that provide updates or press releases without full financial reports.
2024-03-06 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release attached as Exhibit 99.1 dated February 16, 2024. The document is short (2153 characters) and primarily serves to furnish information rather than present detailed financial data or a full report. It explicitly states that the attached press release is being furnished and not filed for certain regulatory purposes. There is no substantive financial data or detailed report content within this document itself. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 6-K filings that provide updates or press releases without full financial statements.
2024-02-16 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.